AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Black Diamond Therapeutics shares rise 1.75% premarket after reporting a narrower Q2 net loss and exploring partnerships for silevertinib development.
ByAinvest
Friday, Aug 8, 2025 4:15 am ET1min read
Black Diamond Therapeutics, Inc. rose 1.75% in premarket trading. The company reported a narrowing of its Q2 net loss to $10.6 million from $19.9 million year-over-year, and it is exploring partnerships to advance the development of silevertinib in NSCLC and GBM. The company expects to release Q4 2025 data for the silevertinib Phase 2 trial and plans an FDA meeting in the first half of 2026 for the NSCLC path. Additionally, Black Diamond is exploring partnerships for the pivotal development of silevertinib and sees cash funding operations into Q4 2027.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet